Skip to main content
SpringerLink
Log in

Rosiglitazone patients mostly switched to new agents

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. TNS Healthcare.Diabetes Patients withdrawn from Avandia Are Most Likely Switched to the New First-in-Class Agents, Januvia or Byetta, According to TNS Healthcare. Media Release: 30 Nov 2007. Available from: URL: http://www.tnsglobal.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosiglitazone patients mostly switched to new agents. Pharmacoecon. Outcomes News 543, 10 (2007). https://doi.org/10.2165/00151234-200705430-00029

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705430-00029

Keywords

Search

Navigation